Imagine a world where cutting-edge protein analysis is no longer confined to specialized labs, but readily available to every researcher, accelerating breakthroughs in disease understanding and treatment. That's the future Olink is building, and a new announcement brings us one giant leap closer!
For years, Olink has championed a clear mission: democratizing high-quality proteomics. What is proteomics, you might ask? Simply put, it's the large-scale study of proteins. Proteins are the workhorses of our cells, and understanding them is crucial for unraveling the complexities of disease. Now, Olink has announced a major advancement: Olink® Reveal is officially verified for seamless sequencing on MGI T1+ and G400 sequencers! This comes complete with optimized protocols and rigorously confirmed performance. You can dive deeper into the specifics here: [Link to article]
But what does this really mean for you, the researcher? This update dramatically expands access to next-generation proteomics. It empowers more labs to generate reliable, high-quality protein data through a streamlined, NGS-based (Next-Generation Sequencing) workflow. Think of NGS as a super-efficient way to read the protein 'code.' This means even more researchers can now explore the intricate world of disease biology at an unprecedented depth, all powered by a carefully curated panel of approximately 1,000 proteins. These aren't just any proteins; they're specifically chosen to deliver truly actionable biological insights. For example, imagine easily identifying key protein biomarkers that can predict a patient's response to a specific drug, leading to more personalized and effective treatments.
And this is the part most people miss... It's not just about generating data; it's about generating meaningful data. The curated protein panel ensures that researchers are focusing on the most relevant targets, saving time and resources while maximizing the potential for discovery.
This latest verification represents another significant step toward Olink's overarching vision: making high-quality proteomics universally accessible. A future where any lab, anywhere, can unlock the power of protein analysis to advance scientific understanding.
But here's where it could get controversial... Some argue that focusing on a pre-selected panel of 1,000 proteins might limit the scope of discovery and potentially overlook important, less-studied proteins. Others might question whether NGS-based proteomics is truly accessible to all labs, considering the initial investment in equipment and expertise.
What are your thoughts? Do you believe that democratizing proteomics through pre-selected panels is the best approach, or should researchers prioritize broader, more exploratory methods? Share your opinion in the comments below!
Citations
Please use one of the following formats to cite this article in your essay, paper or report:
APA
Olink®- Part of Thermo Fisher Scientific. (2025, November 13). Bringing accessible NGS-based proteomics to even more labs. News-Medical. Retrieved on November 13, 2025 from https://www.news-medical.net/news/20251113/Bringing-accessible-NGS-based-proteomics-to-even-more-labs.aspx.
MLA
Olink®- Part of Thermo Fisher Scientific. "Bringing accessible NGS-based proteomics to even more labs". News-Medical. 13 November 2025. <https://www.news-medical.net/news/20251113/Bringing-accessible-NGS-based-proteomics-to-even-more-labs.aspx>.
Chicago
Olink®- Part of Thermo Fisher Scientific. "Bringing accessible NGS-based proteomics to even more labs". News-Medical. https://www.news-medical.net/news/20251113/Bringing-accessible-NGS-based-proteomics-to-even-more-labs.aspx. (accessed November 13, 2025).
Harvard
Olink®- Part of Thermo Fisher Scientific. 2025. Bringing accessible NGS-based proteomics to even more labs. News-Medical, viewed 13 November 2025, https://www.news-medical.net/news/20251113/Bringing-accessible-NGS-based-proteomics-to-even-more-labs.aspx.
Terms
While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.
Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.
Please do not ask questions that use sensitive or confidential information.
Read the full Terms & Conditions (https://www.news-medical.net/life-sciences/terms) .
